Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 17/20 | 0.77 |
| ▸ | ADRA1D | P25100 | 16/20 | 0.75 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.75 |
| ▸ | ADRA2C | P18825 | 11/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 9/20 | 0.75 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7576064 | 0.99 | ADRA1A (0.77) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| Fumaric Acid SCHEMBL6372755 | 0.91 | ADRA1A (0.65) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL6371153 | 0.88 | ADRA1A (0.76) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL6315485 | 0.87 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL6371025 | 0.86 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL6368293 | 0.84 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL6365534 | 0.84 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| Hydrochloric Acid SCHEMBL6367759 | 0.82 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| Fumaric Acid SCHEMBL6371377 | 0.80 | ADRA1A (0.64) | ADRA1AADRA1DADRA1BADRA2CADRA2A | |
| SCHEMBL6436107 | 0.79 | ADRA1A (0.74) | ADRA1AADRA1DADRA1BADRA2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007509897-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682110-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | claimed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| WO-2005046664-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | claimed |
| US-6884801-B1 | Imidazoline derivatives as alpha-1A adrenoceptor ligands | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-26 | — | — | US | claimed |
| JP-2002543187-A | — | — | 2002-12-17 | — | — | JP | claimed |
| EP-1175406-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2002-01-30 | — | — | EP | claimed |
| WO-2000066563-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-11-09 | — | — | WO | claimed |
| EP-1682110-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| WO-2005046664-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-6884801-B1 | Imidazoline derivatives as alpha-1A adrenoceptor ligands | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1175406-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066563-A1 | IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRA1A 6/4885ADRA1D 9/4885ADRA1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.